The semaglutide tablet for weight loss: what it is, what it isn't

Rybelsus and Wegovy tablets are not interchangeable, here is why that matters

The most common misconception floating around is that any semaglutide tablet can be used for weight loss. It cannot. Rybelsus contains semaglutide at 3 mg, 7 mg and 14 mg, those strengths are licensed exclusively for type 2 diabetes management, not for weight loss, and the MHRA has not approved them for that purpose. Wegovy tablets sit on a completely separate dose ladder: 1.5 mg, 4 mg, 9 mg and 25 mg, formulated to reach the concentrations needed for meaningful weight reduction.

This distinction has real consequences. Sourcing oral semaglutide without a prescription from an unverified seller carries two risks simultaneously: you may receive the wrong product, and you lose any clinical oversight of how you are using it. The specific uses of semaglutide tablets depend entirely on which formulation a prescriber has authorised for you and why.

A prescriber assessing you for Wegovy tablets is not simply checking a box. They are weighing your full medical picture against the licensed criteria, reviewing any medicines you already take, and deciding whether a tablet or an injection better fits your situation. Getting that assessment right at the start saves a lot of trouble later. You can read more about the tablet formulation in detail if you want to understand the absorption mechanism before your consultation.

How you take the tablet, and why the morning routine is non-negotiable

Oral semaglutide is notoriously fussy about absorption. The SNAC enhancer does its job only under very specific stomach conditions: the tablet must be taken first thing in the morning, before any food or drink other than a small amount of plain water, up to around 120 ml. Then you wait at least 30 minutes before eating, drinking coffee, or taking any other oral medicines. Swallow the tablet whole.

Miss that window and the medicine largely fails to absorb. It is not like paracetamol, where timing is flexible. The OASIS 4 trial reporting approximately 13.6% average weight loss was conducted under these conditions, and the higher figure (around 16.6% among those who adhered fully) reflects how closely adherence and outcome are connected in this treatment. Both figures come from the 64-week phase 3 data cited at the time of MHRA approval in June 2026.

The upside is storage. No fridge needed, no cold chain to maintain on holiday. The tablet goes in your bag, your desk drawer, or wherever you keep your morning vitamins. One of our prescribers at the nume clinical team (sorry, at the nume clinical team) describes it as the option patients ask about most when they travel regularly for work. That said, the injection and the tablet are both valid routes; which suits you is a clinical conversation, not a lifestyle preference alone.

A brief note on cost: private treatment costs vary by dose and provider, and if you are weighing up options, our Wegovy tablet pricing page sets out what a single transparent price actually covers.

Who the tablet is licensed for, and the dose escalation your prescriber will follow

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. Treatment is meant to run alongside a reduced-calorie diet and increased physical activity, the tablet handles appetite regulation, but the lifestyle side still matters.

Treatment begins at 1.5 mg and steps up through 4 mg and 9 mg to the 25 mg maintenance dose, spending at least one month at each level. Rushing the titration to chase faster results is not how it works; the gradual increase is designed to reduce gastrointestinal side effects, which are the most commonly reported in this class. In the OASIS 4 trial, around 74% of people taking the tablet reported GI effects at some point, compared with about 42% on placebo. Most were mild to moderate and settled over time.

The tablet is not currently available on the NHS, a NICE appraisal would be required first, and no appraisal has been initiated at the time of writing (summer 2026). Private prescription is the only route for now. You can explore the full picture of oral semaglutide treatment or look at how the Wegovy tablet compares with the injection form if you are still deciding.

Side effects to know, and when to take them seriously

Nausea is the most frequently mentioned effect, especially in the early weeks and after each dose step. Vomiting, loose stools, constipation and indigestion round out the common picture. These are the same GI effects seen across the GLP-1 class and are covered in detail on the NHS guidance for semaglutide. They tend to ease as your body adjusts, though the adjustment period is real, not a rumour invented by people who stopped too soon.

A smaller number of people experience pancreatitis. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk across GLP-1 medicines. Severe stomach pain that extends toward the back, with or without vomiting, is the signal to seek urgent medical attention rather than wait and see. Report any suspected side effects using the MHRA Yellow Card scheme, which also accepts reports about suspect sellers or counterfeit products.

Wegovy tablets are not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. They are not licensed for anyone under 18. If any of these apply to you, or if you have a history of pancreatitis or medullary thyroid carcinoma, those are exactly the kinds of details a prescriber needs before anything else. Our treatment overview covers how different options compare for people with more complex medical histories.

If you have read enough and want to find out whether the tablet is right for your situation, speak to our prescribers, a GPhC-registered clinician reviews every consultation the same day, with no waiting list.